Bioxyne has announced that it has made and supplied the nation’s first pharmaceutical-grade cannabis gummies, in what it calls “a significant milestone for Australian pharmaceutical manufacturing”.
The gummies (or pastilles) were made under Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration by Bioxyne’s wholly-owned subsidiary, Breathe Life Sciences.
BLS received deposits on purchase orders totalling approximately $2 million for gummies – the first commercial sale of Australian-made edible cannabis products, it said.
“This is a significant milestone for Australian pharmaceutical manufacturing and the medical cannabis industry as a whole,” said Jason Stephens, General Manager of BLS Australia, in a statement on Wednesday.
“Australia is fast becoming a global medical cannabis hub and BLS is quickly becoming a substantial proponent of that.”
Bioxyne cited a market forecast for prescription cannabis edibles in Australia to grow from about $5 million per year in 2023 to “a potential $150 million per year opportunity.”
BLS said it is currently scaling up production capacity from 2 million single doses per month to 6 million. This follows a two-year manufacturing and supply agreement with an unnamed local largest cannabis company, forecasted to generate a minimum of $28 million in revenues.
The company announced that its GMP licence for medical cannabis, psilocybin and MDMA in February.
According to its website, BLS is based in Sydney, with production, warehouse and import/export operations on the Gold Coast as well as Japan, the UK and the Czech Republic. It also offers lab services and private label manufacturing to wellness product companies.
